Overcoming reimbursement obstacles for cell and gene therapies

The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece.

In fact, the US Food and Drug Administration (FDA) recently announced it anticipates approving as many as 10 to 20 cell and gene therapy products in the next six years.

While the therapies have the potential to treat and possibly cure some of the rarest and most complex diseases, there lie a number of challenges the industry must overcome to ensure their commercial success.